6,618 research outputs found
Letter from Cy Donner to Michi Weglyn, June 2, 1967
No full textA letter from Cy Donner to Michi Weglyn encouraging her to come out to California to talk to producers about two shows called "Youthquake" and "Pretty Talk".These materials are from box 73 and 74 of the Frank Chin Papers. The Frank Chin Papers contain personal and professional correspondence between Frank Chin and Michi Weglyn relating to particular projects on which either author was working as well as files related to the Day of Remembrance Tribute to Michi Weglyn
Efficacy of light therapy on nonseasonal depression among elderly adults: a systematic review and meta-analysis [Corrigendum]
No full textCH Chang, CY Liu, SJ Chen, HC Tsai. Neuropsychiatr Dis Treat. 2018;14:3091–3102.The authors have advised that they listed the second affiliation in the author list of the paper incorrectly. The current affiliation number 2 “Department of Psychiatry & Brain Disease Research Center, China Medical University Hospital, Taichung, Taiwan” should instead appear as “An Nan Hospital, China Medical University, Tainan, Taiwan”.Read the original articl
CY-09 Alleviates the Depression-like Behaviors via Inhibiting NLRP3 Inflammasome-Mediated Neuroinflammation in Lipopolysaccharide-Induced Mice
No full textDepression
is a serious mental illness, mainly characterized
as
large mood swings and sleep, diet, and cognitive function disorders.
NLPR3, one of the inflammasomes that can be activated by a variety
of stimuli to promote the maturation and secretion of pro-inflammatory
cytokines, has been considered to be involved in the pathophysiology
of depression. In this study, the putative role of CY-09, a selective
and direct inhibitor of NLRP3, was evaluated in the lipopolysaccharide
(LPS)-induced mice. The results of the study indicated that CY-09
significantly decreased the levels of NLRP3 in the hippocampus of
LPS-induced mice. In addition, CY-09 increased the sucrose preference
and shortened the immobility time in LPS-induced mice, suggesting
the antidepressant-like effects of inhibiting NLRP3 inflammasome.
Biochemical analysis showed that LPS significantly activated the NLRP3/ASC/cytokine
signaling pathway and caused microglial activation, while CY-09 prevented
the changes. Moreover, CY-09 increased the brain-derived neurotrophic
factor (BDNF) only in microglia but not in the whole hippocampus.
Meanwhile, CY-09 did not promote neurogenesis in the hippocampus of
LPS mice. In conclusion, the results of the study showed that the
antidepressant-like effects of NLRP3 inhibitor CY-09 were mediated
by alleviating neuroinflammation in microglia and independent of the
neurotrophic function in the hippocampus
Factors associated with the diagnosis of neurodevelopmental disorders: a population-based longitudinal study
No full textIncreased risks of congenital, neurological and endocrine disorders associated with autism in preschool children: cognitive ability differences
No full textUrbanicity-related Variation in Help-seeking and Services Utilization among Preschool-age Children with Autism in Taiwan
No full textFTIR spectra of the CY, PVA, PVA/CNF, CY/PVA and CY/PVA/CNF films.
No full textFTIR spectra of the CY, PVA, PVA/CNF, CY/PVA and CY/PVA/CNF films.</p
Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia
Full text linkThe choice of conditioning regimen before allogeneic stem cell transplantation (SCT) in patients with acute lymphoblastic leukemia (ALL) is important. We retrospectively compared outcomes of medium-dose VP-16/cyclophosphamide/total body irradiation (VP/CY/TBI) regimen and CY/TBI. Five hundred and twenty-nine patients (VP/CY/TBI: n = 35, CY/TBI: n = 494) who met all of the following criteria were compared: first time for SCT, aged 15-59 years; first or second complete remission at SCT; bone marrow or peripheral blood as stem cell source; and HLA phenotypically matched donor. Median age of the patients was 34 years, and patients who received VP/CY/TBI were younger (28 years vs. 34 years, P = 0.02). Cumulative incidences of relapse and non-relapse mortality (NRM) were higher for patients who received CY/TBI (P = 0.01 for relapse, P < 0.01 for NRM). After a median follow-up period of 36.9 months, 5-year overall survival (OS) rates were 82.2% in the VP/CY/TBI group and 55.2% in the CY/TBI group. OS, and disease-free survival (DFS) in the VP/CY/TBI group were shown to be significantly better by multivariate analysis [hazard ratio: 0.21 (95% confidence interval: 0.06-0.49) for DFS, hazard ratio: 0.25 (95% confidence interval: 0.08-0.59) for OS]. VP/CY/TBI was associated with a lower relapse rate and no increase in NRM, resulting in better survival than that in CY/TBI for adult ALL patients
- …
